Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Nuvo Pharmaceuticals Inc (OTC: NRIFF).

Full DD Report for NRIFF

You must become a subscriber to view this report.


Recent News from (OTC: NRIFF)

Nuvo Pharma extends negotiation period for Aralez assets
Nuvo Pharmaceuticals ( OTCQX:NRIFF ) reports that it has extended the negotiation period with Aralez Pharmaceuticals and Deerfield Management for its planned acquisition of a portfolio of more than 20 revenue-generating Aralez assets. More news on: Nuvo Pharmaceuticals Inc, Healthcare st...
Source: SeekingAlpha
Date: August, 20 2018 10:41
Nuvo Pharmaceuticals(TM) Announces Extension of Exclusivity Period with Aralez and Deerfield
MISSISSAUGA, ON , Aug. 20, 2018 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a globally focused, healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that it has extended the ...
Source: PR Newswire
Date: August, 20 2018 07:30
Nuvo Pharmaceuticals(TM) Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
Nuvo Pharmaceuticals™ Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals Canada NewsWire MISSISSAUGA, ON, Aug. 10, 2018 - Would result in significant expansion of revenue and adjusted EBITDA – - Woul...
Source: Canada Newswire
Date: August, 10 2018 06:19
Nuvo Pharmaceuticals  reports Q2 results
Nuvo Pharmaceuticals  ( OTCQX:NRIFF ): Q2 net income of $1.1M More news on: Nuvo Pharmaceuticals Inc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 02 2018 07:42
Nuvo Pharmaceuticals(TM) Announces 2018 Second Quarter Results
- Reports $1.9 million of Adjusted EBITDA on $5.9 million of Revenue - - Finished the Quarter with $8.7 million of Cash and no Debt - - Nuvo to Host Conference Call/Audio Webcast August 2 nd at 8:30 a.m. ET - MISSISSAUGA, ON , Aug. 2, 2018 /PRNewswire/ - Nuvo Phar...
Source: PR Newswire
Date: August, 02 2018 07:30
Nuvo Pharmaceuticals(TM)(Ireland) Limited Enters into Resultz® License and Supply Agreement with Fagron Belgium NV for Belgium, the Netherlands and Luxembourg
Nuvo Pharmaceuticals™(Ireland) Limited Enters into Resultz® License and Supply Agreement with Fagron Belgium NV for Belgium, the Netherlands and Luxembourg Canada NewsWire MISSISSAUGA, ON, July 23, 2018 MISSISSAUGA, ON , July 23, 2018 /CNW/ - Nuvo P...
Source: Canada Newswire
Date: July, 23 2018 07:15
Nuvo Pharmaceuticals(TM) Announces Director Election Results of its Annual General Meeting
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting Canada NewsWire MISSISSAUGA, ON, May 10, 2018 MISSISSAUGA, ON , May 10, 2018 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF) a commercial h...
Source: Canada Newswire
Date: May, 10 2018 17:13
Nuvo Pharmaceuticals(TM) Announces 2018 First Quarter Results
- Nuvo to Host Conference Call/Audio Webcast May 10th at 7:45 a.m. ET - MISSISSAUGA, ON , May 10, 2018 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a commercial healthcare company with a portfolio of commercial products and pharmaceutic...
Source: PR Newswire
Date: May, 10 2018 07:00
Nuvo Pharmaceuticals Inc. Presentation Now Available for On-Demand Viewing
Nuvo Pharmaceuticals Inc. Presentation Now Available for On-Demand Viewing Canada NewsWire MISSISSAUGA, Canada, April 16, 2018 Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation M...
Source: Canada Newswire
Date: April, 16 2018 08:35
Nuvo Pharmaceuticals Inc. to Webcast, Live, at VirtualInvestorConferences.com April 11, 2018
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com MISSISSAUGA, Ontario , April 9, 2018 /PRNewswire/ -- Nuvo Pharmaceuticals Inc.   (OTCQX: NRIFF, TSX: NRI), based in Canada , ...
Source: PR Newswire
Date: April, 09 2018 08:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A1.656N/AN/A76
2018-12-131.591.6561.6561.5910,400
2018-12-121.6541.6541.6541.6543,600
2018-12-111.67041.67041.67041.67041,290
2018-12-101.7111.7111.7111.711915

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-10-2610,00010,000100.0000Short
2018-09-131,2003,38535.4505Short
2018-09-11200200100.0000Short
2018-09-102,7003,20884.1646Short
2018-09-066,0006,00499.9334Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NRIFF.


About Nuvo Pharmaceuticals Inc (OTC: NRIFF)

Logo for Nuvo Pharmaceuticals Inc (OTC: NRIFF)

Nuvo TSX:NRI is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. Nuvo has three commercial products that are available in a number of countries Pennsaid , Pennsaid and the heated lidocaine/tetracaine patch. Pennsaid is sold in the U.S. by Horizon Pharma plc NASDAQ:HZNP and is available for partnering in certain other territories around the world. Nuvo manufactures Pennsaid for the global market and Pennsaid for the U.S. market at its FDA, Health Canada and E.U. approved manufacturing facility in Varennes, Qu bec.

 

Contact Information

 

 

Current Management

  • John London / CEO
  • Jesse Ledger / President
  • Nicole Rusaw / Interim CFO
  • MaryJane Burkett / CFO
  • Katina Loucaides / Vice President, Secretary, General Counsel
  • Daniel Chicoine / Chairman
  • David Copeland / Independent Director, Audit Committee Member
  • Anthony Dobranowski / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Robert Harris / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • John London /
  • Jacques Messier / Independent Director, Compensation Committee Member, Nominating Committee Member

Current Share Structure

  • Market Cap: $29,904,117 - 03/12/2018
  • Issue and Outstanding: 11,550,897 - 11/13/2017
  • Float: 8,442,891 - 10/31/2017

 


Recent Filings from (OTC: NRIFF)

Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: November, 20 2017
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: November, 20 2017
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: November, 20 2017
Corporate Bylaws - Corporate Bylaws
Filing Type: Corporate Bylaws - Corporate BylawsFiling Source: OTC Markets
Filing Date: November, 20 2017
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: November, 20 2017
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: November, 20 2017
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: November, 20 2017
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: November, 20 2017
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: November, 20 2017
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: November, 20 2017

 

 


Daily Technical Chart for (OTC: NRIFF)

Daily Technical Chart for (OTC: NRIFF)


Stay tuned for daily updates and more on (OTC: NRIFF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: NRIFF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NRIFF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NRIFF and does not buy, sell, or trade any shares of NRIFF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/